# LAS Vegas Sands Corp: financial statements, quarterly

LVS · NYSE · CIK 1300514 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lvs.md) · [Financials](/companies/lvs/financials.md) · [Filings](/companies/lvs/filings.md) · [Insiders](/companies/lvs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lvs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,915](/filings/0001300514-25-000040.md) | [2,959](/filings/0001300514-26-000013.md) | [2,761](/filings/0001300514-26-000013.md) | [2,682](/filings/0001300514-26-000013.md) | [2,896](/filings/0001300514-26-000013.md) | [2,862](/filings/0001300514-26-000046.md) | [3,175](/filings/0001300514-26-000085.md) | [3,331](/filings/0001300514-26-000103.md) | [3,649](/filings/0001300514-26-000013.md) | [3,585](/filings/0001300514-26-000046.md) | [3,154](/filings/0001300514-26-000085.md) | [3,216](/filings/0001300514-26-000103.md) |
| Research and development | $m | [65.0 d](/filings/0001300514-26-000013.md) | [53.0](/filings/0001300514-25-000095.md) | [61.0](/filings/0001300514-25-000144.md) | [55.0](/filings/0001300514-25-000163.md) | [59.0 d](/filings/0001300514-26-000013.md) | [69.0](/filings/0001300514-26-000046.md) | [69.0](/filings/0001300514-26-000085.md) | [72.0](/filings/0001300514-26-000103.md) | [59.0 d](/filings/0001300514-26-000013.md) | [41.0](/filings/0001300514-26-000046.md) | [43.0](/filings/0001300514-26-000085.md) | [37.0](/filings/0001300514-26-000103.md) |
| Selling, general and administrative | $m | [287 d](/filings/0001300514-26-000013.md) | [286](/filings/0001300514-25-000095.md) | [268](/filings/0001300514-25-000144.md) | [293](/filings/0001300514-25-000163.md) | [303 d](/filings/0001300514-26-000013.md) | [273](/filings/0001300514-26-000046.md) | [292](/filings/0001300514-26-000085.md) | [308](/filings/0001300514-26-000103.md) | [315 d](/filings/0001300514-26-000013.md) | [302](/filings/0001300514-26-000046.md) | [331](/filings/0001300514-26-000085.md) | [333](/filings/0001300514-26-000103.md) |
| Operating income | $m | [710](/filings/0001300514-25-000040.md) | [717](/filings/0001300514-26-000013.md) | [591](/filings/0001300514-26-000013.md) | [504](/filings/0001300514-26-000013.md) | [590](/filings/0001300514-26-000013.md) | [609](/filings/0001300514-26-000046.md) | [783](/filings/0001300514-26-000085.md) | [719](/filings/0001300514-26-000103.md) | [707](/filings/0001300514-26-000013.md) | [904](/filings/0001300514-26-000046.md) | [618](/filings/0001300514-26-000085.md) | [618](/filings/0001300514-26-000103.md) |
| Interest expense | $m | [190 d](/filings/0001300514-26-000013.md) | [182](/filings/0001300514-25-000095.md) | [186](/filings/0001300514-25-000144.md) | [179](/filings/0001300514-25-000163.md) | [180 d](/filings/0001300514-26-000013.md) | [174](/filings/0001300514-26-000046.md) | [194](/filings/0001300514-26-000085.md) | [187](/filings/0001300514-26-000103.md) | [191 d](/filings/0001300514-26-000013.md) | [188](/filings/0001300514-26-000046.md) | [189](/filings/0001300514-26-000085.md) | [186](/filings/0001300514-26-000103.md) |
| Income tax | $m | [123 d](/filings/0001300514-26-000013.md) | [17.0](/filings/0001300514-25-000095.md) | [72.0](/filings/0001300514-25-000144.md) | [50.0](/filings/0001300514-25-000163.md) | [69.0 d](/filings/0001300514-26-000013.md) | [63.0](/filings/0001300514-26-000046.md) | [90.0](/filings/0001300514-26-000085.md) | [91.0](/filings/0001300514-26-000103.md) | [103 d](/filings/0001300514-26-000013.md) | [107](/filings/0001300514-26-000046.md) | [88.0](/filings/0001300514-26-000085.md) | [102](/filings/0001300514-26-000103.md) |
| Net income | $m | [382](/filings/0001300514-25-000040.md) | [494](/filings/0001300514-26-000013.md) | [353](/filings/0001300514-26-000013.md) | [275](/filings/0001300514-26-000013.md) | [324](/filings/0001300514-26-000013.md) | [352](/filings/0001300514-26-000046.md) | [461](/filings/0001300514-26-000085.md) | [419](/filings/0001300514-26-000103.md) | [395](/filings/0001300514-26-000013.md) | [567](/filings/0001300514-26-000046.md) | [346](/filings/0001300514-26-000085.md) | [304](/filings/0001300514-26-000103.md) |
| Diluted EPS | $ per share | [0.50](/filings/0001300514-25-000040.md) | [0.66](/filings/0001300514-26-000013.md) | [0.48](/filings/0001300514-26-000013.md) | [0.38](/filings/0001300514-26-000013.md) | [0.45](/filings/0001300514-26-000013.md) | [0.49](/filings/0001300514-26-000046.md) | [0.66](/filings/0001300514-26-000085.md) | [0.61](/filings/0001300514-26-000103.md) | [0.58](/filings/0001300514-26-000013.md) | [0.85](/filings/0001300514-26-000046.md) | [0.53](/filings/0001300514-26-000085.md) | [0.48](/filings/0001300514-26-000103.md) |
| Basic EPS | $ per share | [0.50](/filings/0001300514-25-000040.md) | [0.66](/filings/0001300514-26-000013.md) | [0.48](/filings/0001300514-26-000013.md) | [0.38](/filings/0001300514-26-000013.md) | [0.45](/filings/0001300514-26-000013.md) | [0.49](/filings/0001300514-26-000046.md) | [0.66](/filings/0001300514-26-000085.md) | [0.61](/filings/0001300514-26-000103.md) | [0.59](/filings/0001300514-26-000013.md) | [0.85](/filings/0001300514-26-000046.md) | [0.53](/filings/0001300514-26-000085.md) | [0.48](/filings/0001300514-26-000103.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [5.1](/filings/0001300514-25-000040.md) | [5.0](/filings/0001300514-24-000070.md) | [4.7](/filings/0001300514-24-000123.md) | [4.2](/filings/0001300514-24-000136.md) | [3.7](/filings/0001300514-26-000013.md) | [3.0](/filings/0001300514-25-000095.md) | [3.5](/filings/0001300514-25-000144.md) | [3.4](/filings/0001300514-25-000163.md) | [3.8](/filings/0001300514-26-000103.md) | [3.3](/filings/0001300514-26-000046.md) | [3.4](/filings/0001300514-26-000085.md) | [2.9](/filings/0001300514-26-000103.md) |
| Current assets | $bn | [5.8](/filings/0001300514-25-000040.md) | [5.6](/filings/0001300514-24-000070.md) | [5.3](/filings/0001300514-24-000123.md) | [4.8](/filings/0001300514-24-000136.md) | [4.3](/filings/0001300514-26-000013.md) | [3.7](/filings/0001300514-25-000095.md) | [4.3](/filings/0001300514-25-000144.md) | [4.2](/filings/0001300514-25-000163.md) | [4.8](/filings/0001300514-26-000103.md) | [4.3](/filings/0001300514-26-000046.md) | [4.3](/filings/0001300514-26-000085.md) | [3.8](/filings/0001300514-26-000103.md) |
| Total assets | $bn | [21.8](/filings/0001300514-26-000013.md) | [21.2](/filings/0001300514-24-000070.md) | [21.1](/filings/0001300514-24-000123.md) | [21.4](/filings/0001300514-24-000136.md) | [20.7](/filings/0001300514-26-000013.md) | [21.2](/filings/0001300514-25-000095.md) | [21.9](/filings/0001300514-25-000144.md) | [21.5](/filings/0001300514-25-000163.md) | [21.9](/filings/0001300514-26-000103.md) | [21.2](/filings/0001300514-26-000046.md) | [19.9](/filings/0001300514-26-000085.md) | [19.4](/filings/0001300514-26-000103.md) |
| Current liabilities | $bn | [4.4](/filings/0001300514-25-000040.md) | [4.3](/filings/0001300514-24-000070.md) | [3.4](/filings/0001300514-24-000123.md) | [5.4](/filings/0001300514-24-000136.md) | [5.8](/filings/0001300514-26-000013.md) | [6.3](/filings/0001300514-25-000095.md) | [3.5](/filings/0001300514-25-000144.md) | [4.7](/filings/0001300514-25-000163.md) | [4.2](/filings/0001300514-26-000103.md) | [4.6](/filings/0001300514-26-000046.md) | [4.3](/filings/0001300514-26-000085.md) | [4.6](/filings/0001300514-26-000103.md) |
| Total liabilities | $bn | [17.7](/filings/0001300514-25-000040.md) | [17.2](/filings/0001300514-24-000070.md) | [17.2](/filings/0001300514-24-000123.md) | [17.7](/filings/0001300514-24-000136.md) | [17.5](/filings/0001300514-26-000013.md) | [18.2](/filings/0001300514-25-000095.md) | [19.6](/filings/0001300514-25-000144.md) | [19.6](/filings/0001300514-25-000163.md) | [20.0](/filings/0001300514-26-000103.md) | [19.6](/filings/0001300514-26-000046.md) | [19.0](/filings/0001300514-26-000085.md) | [19.5](/filings/0001300514-26-000103.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [4.1](/filings/0001300514-25-000040.md) | [4.0](/filings/0001300514-24-000070.md) | [3.8](/filings/0001300514-24-000123.md) | [3.4](/filings/0001300514-24-000136.md) | [2.9](/filings/0001300514-26-000013.md) | [2.7](/filings/0001300514-25-000095.md) | [2.0](/filings/0001300514-25-000144.md) | [1.6](/filings/0001300514-25-000163.md) | [1.6](/filings/0001300514-26-000103.md) | [1.2](/filings/0001300514-26-000046.md) | [0.6](/filings/0001300514-26-000085.md) | [(0.3)](/filings/0001300514-26-000103.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,006 d](/filings/0001300514-26-000013.md) | [714](/filings/0001300514-25-000095.md) | [814 d](/filings/0001300514-25-000144.md) | [761 d](/filings/0001300514-25-000163.md) | [915 d](/filings/0001300514-26-000013.md) | [526](/filings/0001300514-26-000046.md) | [178 d](/filings/0001300514-26-000085.md) | [1,115 d](/filings/0001300514-26-000103.md) | [1,204 d](/filings/0001300514-26-000013.md) | [731](/filings/0001300514-26-000046.md) | [682 d](/filings/0001300514-26-000085.md) | [870 d](/filings/0001300514-26-000103.md) |
| Capital expenditure | $m | [325 d](/filings/0001300514-26-000013.md) | [196](/filings/0001300514-25-000095.md) | [285 d](/filings/0001300514-25-000144.md) | [539 d](/filings/0001300514-25-000163.md) | [547 d](/filings/0001300514-26-000013.md) | [379](/filings/0001300514-26-000046.md) | [286 d](/filings/0001300514-26-000085.md) | [229 d](/filings/0001300514-26-000103.md) | [274 d](/filings/0001300514-26-000013.md) | [194](/filings/0001300514-26-000046.md) | [332 d](/filings/0001300514-26-000085.md) | [281 d](/filings/0001300514-26-000103.md) |
| Dividends paid | $m | [152 d](/filings/0001300514-26-000013.md) | [151](/filings/0001300514-25-000095.md) | [148 d](/filings/0001300514-25-000144.md) | [146 d](/filings/0001300514-24-000136.md) | [145 d](/filings/0001300514-26-000013.md) | [179](/filings/0001300514-25-000095.md) | [246 d](/filings/0001300514-25-000144.md) | [239 d](/filings/0001300514-26-000103.md) | [169 d](/filings/0001300514-26-000013.md) | [202](/filings/0001300514-26-000046.md) | [328 d](/filings/0001300514-26-000085.md) | [193 d](/filings/0001300514-26-000103.md) |
| Share repurchases | $m | [505 d](/filings/0001300514-26-000013.md) | [450](/filings/0001300514-25-000095.md) | [400 d](/filings/0001300514-25-000144.md) | [450 d](/filings/0001300514-25-000163.md) | [450 d](/filings/0001300514-26-000013.md) | [416](/filings/0001300514-26-000046.md) | [800 d](/filings/0001300514-26-000085.md) | [500 d](/filings/0001300514-26-000103.md) | [501 d](/filings/0001300514-26-000013.md) | [753](/filings/0001300514-26-000046.md) | [788 d](/filings/0001300514-26-000085.md) | [950 d](/filings/0001300514-26-000103.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends, us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [766](/filings/0001300514-24-000070.md) | [767](/filings/0001300514-24-000123.md) | [766](/filings/0001300514-24-000136.md) | [752](/filings/0001300514-25-000095.md) | [741](/filings/0001300514-25-000144.md) | [731](/filings/0001300514-25-000163.md) | [713](/filings/0001300514-26-000046.md) | [696](/filings/0001300514-26-000085.md) | [685](/filings/0001300514-26-000103.md) | [671](/filings/0001300514-26-000046.md) | [656](/filings/0001300514-26-000085.md) | [640](/filings/0001300514-26-000103.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 626,990,133 at 2026-10-21, from the cover of the [10-Q filed 2026-10-23](/filings/0001300514-26-000103.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.